Can a drug combo shrink liver tumors enough for surgery?
NCT ID NCT02350530
First seen May 31, 2026 · Last updated Jun 19, 2026 · Updated 3 times
Summary
This study tested whether adding the targeted drug bevacizumab to a powerful three-drug chemotherapy regimen (FOLFOXIRI) could shrink liver tumors from colorectal cancer enough to allow surgical removal. The trial enrolled 138 people with a specific genetic mutation (RAS mutation) whose liver tumors could not be removed at the start. The main goal was to see how many patients could then have their tumors completely removed after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510655, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FOLFOXIRI (a combination of four chemotherapy drugs) with or without bevacizumab (a targeted therapy that blocks blood vessel growth to tumors)
What this could lead to
If successful, this approach could help more people with advanced colorectal cancer become eligible for liver surgery, potentially improving long-term survival.
What could go wrong
This is a phase 2 trial with only 138 participants, so results are preliminary. Adding bevacizumab increases the risk of side effects like high blood pressure, bleeding, and severe neutropenia (low white blood cell count).
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.